Embryonic stem cell-derived cardiomyocytes for ischemic myocardium

The aim of this study is to demonstrate the ability of Human embryonic stem cell (hESC)-derived cardiomyocytes for treating ischemic myocardium. hESC-derived cardiomyocytes were transplanted by direct injection into ischemic regions of the left ventricle after 30 minutes of temporary left anterior descending (LAD) coronary artery occlusion. Transplantation of hESC-derived cardiomyocytes resulted in improved heart function and long-term engraftment of the cells.